<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beremagene geperpavec: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beremagene geperpavec: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Beremagene geperpavec: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="141540" href="/d/html/141540.html" rel="external">see "Beremagene geperpavec: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="141598" href="/d/html/141598.html" rel="external">see "Beremagene geperpavec: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58339134"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vyjuvek</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58253885"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gene Therapy, Herpes Simplex Virus Type 1;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F58305166"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59f7f017-2a60-4fc6-806e-08ea9c13258a">Dystrophic epidermolysis bullosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dystrophic epidermolysis bullosa:</b>
<b>Topical:</b> Maximum weekly dose: Apply up to 3.2 × 10<sup>9</sup> plaque-forming units (maximum weekly volume: 1.6 mL) once weekly. <b>Note:</b> It may not be possible to apply gel to all wounds at each treatment visit. The total dose for wounds &gt;60 cm<sup>2</sup> should be calculated by wound size until the maximum weekly dose is reached.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Beremagene geperpavec Dose by Wound Size</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Wound area</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Volume</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;20 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">4 × 10<sup>8</sup> plaque-forming units</p></td>
<td align="left">
<p style="text-indent:0em;">0.2 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">8 × 10<sup>8</sup> plaque-forming units</p></td>
<td align="left">
<p style="text-indent:0em;">0.4 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to 60 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">1.2 × 10<sup>9</sup> plaque-forming units</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mL</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58305168"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58305169"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F58305167"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F58299959"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="141540" href="/d/html/141540.html" rel="external">see "Beremagene geperpavec: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db6420fd-8489-459b-ba04-247ca2b95be1">Dystrophic epidermolysis bullosa, wound treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dystrophic epidermolysis bullosa, wound treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Application should be performed by a health care professional.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: Topical: Apply appropriate amount of gel based on wound size (see table) to wounds once weekly until wounds closed. Do not exceed maximum weekly dose. It may not be possible to treat all wounds at each treatment visit; treat wounds until closed before selecting new wound(s); if wounds reopen, prioritize treating previously treated areas.</p>
<p style="text-indent:-2em;margin-left:6em;">Dose by wound size:</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>
<b>Beremagene Geperpavec Dosing by Wound Size</b></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">Wound area</p></th>
<th align="left">
<p style="text-indent:0em;">Dose<sup>a</sup></p></th>
<th align="left">
<p style="text-indent:0em;">Volume</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>Do not exceed age-based maximum weekly dose.</p>
<p style="text-indent:0em;">
<sup>b</sup> PFU = plaque-forming units.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;20 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">4 × 10<sup>8</sup> PFU<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;">0.2 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">8 × 10<sup>8</sup> PFU</p></td>
<td align="left">
<p style="text-indent:0em;">0.4 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to 60 cm<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">1.2 × 10<sup>9</sup> PFU</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;60 cm<sup>2</sup></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Calculate dose based on areas above, not to exceed age-based weekly maximum.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Maximum weekly doses:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;3 years: Topical: Maximum dose: 1.6 × 10<sup>9</sup> PFU (0.8 mL) once weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥3 years and Adolescents: Topical: Maximum dose: 3.2 × 10<sup>9</sup> PFU (1.6 mL) once weekly.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58299966"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58299967"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F58265368"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (6%), pruritus (10%), skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%), rhinorrhea (6%)</p></div>
<div class="block coi drugH1Div" id="F58253856"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F58305161"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental exposure: Avoid direct contact (eg, scratching, touching) with treated wounds and dressing for ~24 hours after application; if exposure occurs, flush exposed area with clean water for at least 15 minutes. Wear protective gloves when administering, changing dressing, and disposing.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To be applied by a health care professional only in a health care setting.</p></div>
<div class="block prod-avail drugH1Div" id="F58253853"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Vyjuvek: FDA approved May 2023; availability anticipated in 3<sup>rd</sup> quarter of 2023.</p></div>
<div class="block foc drugH1Div" id="F58339135"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyjuvek: Beremagene geperpavec-svdt 5 billion PFU/2.5 mL (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F58339133"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58481994"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Vyjuvek External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5000000000PFU/2.5ML (per mL): $11,640.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F58305170"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> For topical use only. Apply to wounds until they are closed before selecting new wounds to treat; it may not be possible to apply gel to all wounds at each treatment visit. If wounds reopen, prioritize open wounds for retreatment. Apply using prepared treatment syringes to wound(s) in droplets spaced evenly within the wound (~1 cm by 1 cm apart); droplet pattern should loosely resemble a grid (see dosing table for dose per approximate wound size). Avoid touching administration syringe to the skin. After administering, apply a slightly larger than the wound nonadherent hydrophobic dressing; place a slightly larger standard dressing on top of the hydrophobic dressing; do not change dressing within ~24 hours of gel application. Clean all surfaces and that have come in contact with the gel with a virucidal (eg, 70% isopropyl alcohol, 6% hydrogen peroxide, or &lt;0.4% ammonium chloride). Dispose of all material (eg, syringe, cleaning material, unused administration syringes containing gel) in a biohazard bag or container.</p></div>
<div class="block admp drugH1Div" id="F58300016"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;">Topical: Application should be performed by a health care professional. Using prepared treatment syringes, apply to wound(s) in droplets spaced evenly within the wound (~1 cm by 1 cm apart); droplet pattern should loosely resemble a grid. Avoid touching administration syringe to the skin. After administering, apply a nonadherent hydrophobic dressing that is slightly larger than the wound; place a slightly larger standard dressing on top of the hydrophobic dressing; do not change dressing within ~24 hours of gel application; direct contact with treated wounds and their dressings should be avoided for ~24 hours. Clean all surfaces that have come in contact with the gel with a virucidal agent (eg, 70% isopropyl alcohol, 6% hydrogen peroxide, &lt;0.4% ammonium chloride); dispose of all material in a biohazard bag or container.</p></div>
<div class="block use drugH1Div" id="F58253855"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Dystrophic epidermolysis bullosa:</b> Treatment of wounds in patients ≥6 months of age with dystrophic epidermolysis bullosa with mutation(s) in the <i>collagen type VII alpha 1 chain (COL7A1</i>) gene.</p></div>
<div class="block cyt drugH1Div" id="F58280593"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58280590"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F58305158"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who may become pregnant should use effective contraception during therapy.</p></div>
<div class="block pri drugH1Div" id="F58305159"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Patients who are pregnant should avoid direct contact with treated dressings and treated wounds, and should not prepare or apply beremagene geperpavec gel to others.</p></div>
<div class="block brc drugH1Div" id="F58305160"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if beremagene geperpavec is present in breast milk following topical application.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F58305165"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Beremagene geperpavec is a herpes simplex virus-1 (HSV-1) vector-based gene therapy that may transduce both keratinocytes and fibroblasts within the nucleus of the cells allowing for production and secretion of COL7; the COL7 molecules form anchoring fibrils, which hold the epidermis and dermis together and help maintain skin integrity. Patients with dystrophic epidermolysis bullosa have lower than normal or no functioning anchoring fibrils.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Vyjuvek (beremagene geperpavec) [prescribing information]. Pittsburgh, PA: Krystal Biotech, Inc; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 141539 Version 12.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
